Diabetic Kidney Disease
SGLT2 inhibitors do not increase risk of fracture compared with other diabetic medications
Starting SGLT2 inhibitors among older patients did not increase risk for skeletal fractures compared with the use of dipeptidyl peptidase inhibitors, according to this study.
Obesity may increase diabetic kidney disease risk, especially in women
Adults with type 2 diabetes and a higher BMI may have an increased risk for diabetic kidney disease, according to study findings published in The Journal of Clinical Endocrinology & Metabolism.
New therapeutic agents may be the ‘holy grail’ for cardiovascular risk management in CKD
Patients with chronic kidney disease are at high risk for adverse cardiovascular events, even after adjusting for traditional risk factors.
Adding empagliflozin to standard of care may be cost-effective for diabetic kidney disease
For commercial insurers and Medicare, it may be cost-effective to add empagliflozin to the standard of care treatment for patients with diabetic kidney disease, according to data published in the American Journal of Kidney Diseases.
Non-albuminuric diabetic kidney disease associated with CVD, CKD risks regardless of eGFR
Aldosterone antagonists play ‘central role’ in heart, kidney disease
Mineralocorticoid receptor antagonists, particularly the most recently approved agent finerenone, should play a “central role” in the treatment of diabetic kidney disease and its related cardiovascular consequences, according to a speaker.
New delivery models can direct improved care for patients with diabetic kidney disease
Treatment of diabetic kidney disease ‘requires multiple drugs’
Multiple pathophysiologic abnormalities contribute the development and progression of diabetic kidney disease, and early intervention with triple or even quadruple therapy is needed to prevent complications, according to a speaker.
Finerenone shows HF benefit in mild to moderate diabetic kidney disease: FIGARO-DKD
The nonsteroidal mineralocorticoid receptor antagonist finerenone reduced CV event risk by 13% for adults with diabetic kidney disease compared with placebo, primarily driven by a 29% reduction in HF hospitalizations.
Finerenone reduces risk for new-onset AF in diabetic kidney disease
Treatment with the mineralocorticoid receptor antagonist finerenone reduced the risk for new-onset AF or flutter by 29% compared with placebo in adults with diabetic kidney disease, according to new data from the FIDELIO-DKD trial.